Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 19 - You Need To See This

Why Quantum BioPharma (QNTM) Stock Is Soaring Today

Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) are on watch Monday morning following a series of updates regarding its lead drug candidate for multiple sclerosis, Lucid-MS. Here’s what investors need to know.

Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

Benzinga

Attorney says heart device did not shock Tennessee man in execution who said he was 'hurting so bad'

The attorney for a Tennessee man who said he was “hurting so bad” during his lethal injection this week says his implanted defibrillator did not shock him

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Becton Dickinson Q3 Beats Estimates On Medical Device Boom

As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company (NYSE:BDX) are reporting robust financial performances that highlight their resilience and strategic adaptability. The company’s stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.

Benzinga

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Benzinga

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Benzinga

Fake Viagra is the UK’s most seized counterfeit drug - here's how to avoid it

Fake Viagra, real problems – the UK’s most seized counterfeit drug revealed

Evening Standard

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Benzinga

Ozempic, Botox, Eliquis: How Tariffs on Europe Could Impact Drug Prices (And What To Do About It)

Most medications come from Europe. Does that mean the new tariffs on the EU will drive drug prices higher?

Kiplinger

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Benzinga

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation (NASDAQ:TWST) has done just that, reporting a surprising third-quarter income that defied analysts’ expectations

Benzinga

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy.

Benzinga

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings.

Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Shares of CommScope Holding Company, Inc. (NASDAQ:COMM) rose sharply in pre-market trading.

Radio France Internationale

Biogaran sale talks renew fears over foreign control of French pharma

France’s top generic drug maker, Biogaran, could soon be sold to a British investment fund, raising new fears about the country’s control over vital medicines.

Benzinga

Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

Avantor Inc. (NYSE:AVTR) stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS.

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.